Biology Atlas

Map / Concepts

concept · intermediate · partly written

Viral vector tropism: which cells a gene delivery virus can enter

Tropism is the set of cell types a vector enters and expresses its gene in; for AAV it is set mainly by the capsid and by the route of giving it.

Also called: tropism, capsid tropism

Tropism in brief

A viral vector is a virus shell with the disease genes removed and a therapeutic gene inside. Which cells it can enter depends on the protein shell (the capsid). Where the vector is put (into a vein or directly into the eye) decides which of those cells it meets first. 123

Reported, not yet replicated

Same vector family, different routes more

Two approved AAV products show the two ways to aim a vector. Zolgensma uses an AAV9 capsid given as one intravenous infusion, and its label states the dose per kilogram of body weight. Luxturna is injected under the retina, so the vector meets the retinal cells directly. Systemic dosing needs a very large number of vector particles per body weight; local dosing needs few, but only works where a needle can reach. 23

Reported, not yet replicated

What the immune system does to tropism more

A vector aimed by its capsid is also seen by the immune system. The Zolgensma label states that trial participants were required to have low antibodies to the AAV9 capsid, and that antibody levels after infusion were very high in the second study. Pre-existing antibodies therefore restrict who can be treated with a given capsid, and the same capsid was not evaluated for re-dosing. 2

Reported, not yet replicated

Plain answer

Tropism is which cells a vector can get into and switch on its gene in. For AAV it is set by the capsid protein shell and by the route of delivery, and it is limited by antibodies that already recognise the shell. 123

Reported, not yet replicated

Why it matters

It explains why gene therapy is not simply inject the gene and it goes where needed: the shell, the route and the immune state of the patient decide whether the gene reaches the target tissue, and a promoter then decides how strongly it is read there. 123

Reported, not yet replicated

Real numbers

Zolgensma dose

The label states a dose of 1.1 x 10^14 vector genomes per kg given as one intravenous infusion. 2

Reported, not yet replicated

Anti-AAV9 antibody cut-off

Trial participants were required to have an anti-AAV9 antibody titre of 1:50 or less; after infusion titres reached at least 1:102,400 in every participant of the second study. 2

Reported, not yet replicated

Teach this

In one sentence

A vector goes where its shell and its route let it go, and the immune system can veto the shell. 1

Reported, not yet replicated

The five-minute version

The capsid decides which cell surface the virus can bind and enter. The route decides which tissue sees it first. A promoter then decides how strongly the gene is read in each cell. Antibodies against a capsid, before or after dosing, can block the same capsid later. 1

Reported, not yet replicated

What a listener will ask

Is a vector aimed like a missile?

Only partly: capsid and route bias where it goes, but other tissues can take it up as well.

Can the same vector be given twice?

The Zolgensma label reports very high antibody levels after infusion and re-dosing was not evaluated.

What sets how strongly the gene is read?

The promoter; see modalities/gene-therapy.

The common wrong idea

The gene goes only to the diseased cells.

Tropism is a bias set by capsid and route, and antibodies can block it; systemic doses can reach other organs too.

The one citation to hand over: 1

Still open here

Not yet written: Equation.

Linked from

Sources

  1. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery (2019). review; opened 2026-11-17 all records citing this
  2. US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, revision 6/2026. FDA (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  3. US Food and Drug Administration. LUXTURNA (voretigene neparvovec-rzyl) prescribing information. FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Status
partly written
Last updated
2026-11-17
Record
content/concepts/viral-vector-tropism.json